Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments

Key PointsBeam Therapeutics is a pioneer in its proprietary gene-editing technique called base editing.Base editing can be more precise than CRISPR/Cas9 by changing just a single letter in the genome rather than cutting through double strands to cut out specific sequences.Beam Therapeutics surprised investors, beating EPS by $2.42 at $1.73 vs. a loss of 69 cents as revenues surged 1,481% to $316.2 million vs $34.12 million, mostly due to its Eli Lilly deal.5 stocks we like better than Beam TherapeuticsBeam ...